Can Patients Move The Rare Disease Treatment Needle In China?
Innovative orphan drug makers have so far largely shunned China but things could be changing. Chinese patient communities tell the Pink Sheet how they are increasingly taking it upon themselves to lobby regulators and persuade drug developers to include China in their clinical development consideration.
You may also be interested in...
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
In a drastic move, China sends top physicians from around the country to Wuhan, finally allows a WHO expert delegation to visit hospitals in the outbreak's epicenter and welcomes foreign experts.